期刊
BIOLOGICAL PSYCHIATRY
卷 83, 期 4, 页码 358-368出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2017.11.020
关键词
Alzheimer's disease; Amyloid; Neurodegeneration; Oligomers; Prion; Therapeutics
资金
- United Kingdom Medical Research Council
- MRC [MC_U123192748, MC_UU_00024/7] Funding Source: UKRI
- Medical Research Council [MC_UU_00024/7, MC_U123192748] Funding Source: researchfish
The initial report that cellular prion protein (PrPC) mediates toxicity of amyloid-beta species linked to Alzheimer's disease was initially treated with scepticism, but growing evidence supports this claim. That there is a high-affinity interaction is now clear, and its molecular basis is being unraveled, while recent studies have identified possible downstream toxic mechanisms. Determination of the clinical significance of such interactions between PrPC and disease-associated amyloid-beta species will require experimental medicine studies in humans. Trials of compounds that inhibit PrP-dependent amyloid-beta toxicity are commencing in humans, and although it is clear that only a fraction of Alzheimer's disease toxicity could be governed by PrPC, a partial, but still therapeutically useful, role in human disease may soon be testable.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据